1. EP-1542: Can proton therapy for head and neck cancer reduce side effects while maintaining target robustness?. (May 2017) Authors: Scandurra, D.; Kierkels, R.G.J.; Gelderman, M.; Credoe, H.M.; Bijl, H.P.; Steenbakkers, R.J.H.M.; Vemer - van de Hoek, J.G.M.; Langendijk, J.A. Journal: Radiotherapy and oncology Issue: Volume 123:(2017:May)Supplement 1 Page Start: S829 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EP-1812: Adaptive VMAT for cT1-2aN0M0 laryngeal cancer: potential risk of target volume over dosage. (April 2016) Authors: Bijl, H.P.; Korevaar, E.W.; Gelderman, M.; Langendijk, J.A.; Kierkels, R.G.J. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S850 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EP-1974: Multi-scenario robustness evaluation; transition to a 'proton proof' alternative to PTV evaluation. (April 2018) Authors: Korevaar, E.W.; Scandurra, D.; Gelderman, M.; Kierkels, R.G.; Knopf, A.C.; Both, S.; Unipan, M.; Eenink, M.G.C.; Langendijk, J.A. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S1073 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗